Pod Save America Hosts Call on Democrats to Cut All Israel Military Aid, No Longer Accept AIPAC Funding
Jews, Israelis Targeted in Austria Amid Surge in Antisemitic Incidents; Local Jewish Community Calls for Action
‘All of Our Strength’: Over 1,000 Pro-Israel Activists Gather in DC for Solidarity Conference
‘Devastated’: Wesley LePatner, Killed in Manhattan Mass Shooting, Was a Jewish Communal, Philanthropic Leader
Sen. Angus King Vows to No Longer Vote for Israel Military Aid Until Gaza Conditions Improve
Europe Won’t Pressure Israel to ‘Commit Suicide’ Amid Gaza Backlash, Palestinian State Push, Says Israeli FM
Israel’s National Soccer Coach Attacked in Athens Before Soccer Fans Chant ‘F–K Israel, Free Palestine’ at Match
New York Judge Sentences Neo-Nazi to 5 Years for Livestreaming Bomb Threats Against Jewish Hospitals
US Pressures Lebanon to Issue Cabinet Decision to Disarm Hezbollah Before Talks Continue
UK Plans to Recognize Palestinian State in September Unless Israel Meets Conditions, Starmer Says
Israeli Pharmaceutical Company on Verge of Major Diabetes Breakthrough
Error: Contact form not found.
by JNS.org
The Israeli pharmaceutical company Oramed is on the verge of developing an oral insulin pill that would be an alternative to such pens. Photo: Wikimedia Commons.
Israel’s Oramed Pharmaceuticals is on the brink of developing a new oral insulin pill that could revolutionize Type 2 diabetes treatment, Israel21c reported.
The pill, which would replace the current method of self-injecting insulin, mimics the natural way insulin is ingested into the body through the mouth. It could help an estimated 371 million people worldwide who are affected by Type 2 diabetes.
Oramed was founded in 2006 by Dr. Miram Kidron, based on her 25 years of research on diabetes at Jerusalem’s Hadassah Media Center. Her son Nadav Kidron is the president and CEO of the company. The insulin pill is designed to target adult diabetics who are not yet insulin dependent, according to Globes.
“We wanted to do more than just replace injections — we wanted to provide an alternative oral medication as an earlier treatment that can extend the second phase [of diabetes progression] and prevent patients from becoming insulin dependent,” Kidron told Israel21c. “That’s the revolution.”
Phase 2 clinical trials are scheduled to begin in the United States.
Oramed also has other diabetes medications in the pipeline, including one that will help balance blood sugar and control appetite—since many people with Type 2 diabetes are overweight.
